Wall Street analysts expect The Joint Corp. (NASDAQ:JYNT) to report sales of $21.61 million for the current quarter, according to Zacks. Two analysts have issued estimates for Joint’s earnings, with estimates ranging from $21.42 million to $21.80 million. Joint posted sales of $17.04 million during the same quarter last year, which suggests a positive year over year growth rate of 26.8%. The company is expected to announce its next earnings report on Thursday, March 3rd.
On average, analysts expect that Joint will report full year sales of $80.39 million for the current fiscal year, with estimates ranging from $80.18 million to $80.60 million. For the next fiscal year, analysts anticipate that the company will post sales of $102.26 million, with estimates ranging from $100.52 million to $104.00 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that cover Joint.
Joint (NASDAQ:JYNT) last posted its quarterly earnings data on Thursday, November 4th. The company reported $0.13 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.04 by $0.09. Joint had a return on equity of 34.65% and a net margin of 23.18%. During the same quarter in the previous year, the company posted $0.11 EPS.
In other news, CFO Jake Singleton sold 2,614 shares of the business’s stock in a transaction that occurred on Wednesday, September 1st. The stock was sold at an average price of $103.12, for a total transaction of $269,555.68. Following the transaction, the chief financial officer now owns 7,734 shares of the company’s stock, valued at approximately $797,530.08. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Ronald V. Davella sold 20,000 shares of the business’s stock in a transaction on Monday, September 13th. The shares were sold at an average price of $101.18, for a total transaction of $2,023,600.00. The disclosure for this sale can be found here. Insiders own 4.60% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of JYNT. Captrust Financial Advisors boosted its holdings in Joint by 117.6% during the 3rd quarter. Captrust Financial Advisors now owns 285 shares of the company’s stock valued at $28,000 after acquiring an additional 154 shares during the period. PNC Financial Services Group Inc. bought a new stake in shares of Joint during the second quarter worth $31,000. USA Financial Portformulas Corp bought a new stake in shares of Joint during the third quarter worth $59,000. O Shaughnessy Asset Management LLC boosted its stake in shares of Joint by 201.3% during the second quarter. O Shaughnessy Asset Management LLC now owns 1,633 shares of the company’s stock valued at $137,000 after purchasing an additional 1,091 shares during the period. Finally, Rational Advisors LLC bought a new position in shares of Joint in the second quarter worth about $153,000. Hedge funds and other institutional investors own 88.98% of the company’s stock.
Shares of JYNT traded down $1.18 during mid-day trading on Thursday, reaching $83.49. The stock had a trading volume of 97,610 shares, compared to its average volume of 213,464. The business has a fifty day moving average of $92.08 and a 200 day moving average of $85.39. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of 70.16 and a beta of 1.18. Joint has a 12 month low of $24.60 and a 12 month high of $111.06.
Joint Company Profile
The Joint Corp. (United States) engages in the development, ownership, operation, support and management of chiropractic clinics. It operates through two segments: Corporate Clinics and Franchise Operations. The Corporate Clinics segment comprises of the operating activities of the company owned or managed clinics.
Recommended Story: What Does Beta Mean In Stock Selection?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Joint and related companies with MarketBeat.com's FREE daily email newsletter.